Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice

This publication has 61 references indexed in Scilit:

• Testing the Right Target and Right Drug at the Right Stage
  Science Translational Medicine, 2011
• β-Secretase Inhibitor Potency Is Decreased by Aberrant β-Cleavage Location of the “Swedish Mutant” Amyloid Precursor Protein
  Journal of Biological Chemistry, 2010
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
  Neurology, 2009
• Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
  EMBO Reports, 2006
• Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β
  The Journal of Neuroscience, 2005
• Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases
  Nature Cell Biology, 2004
• Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
  Science, 2002
• Amyloid β Protein Starting Pyroglutamate at Position 3 Is a Major Component of the Amyloid Deposits in the Alzheimer's Disease Brain
  Biochemical and Biophysical Research Communications, 2000
• Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques
  Neuron, 1995
• Fusion between immunoglobulin‐secreting and nonsecreting myeloma cell lines
  European Journal of Immunology, 1976